Squalene-Based Nano-Assemblies Improve the Pro-Autophagic Activity of Trehalose

Giulia Frapporti 1,†, Eleonora Colombo 2,†, Hazem Ahmed 2,3*, Giulia Assoni 1,2, Laura Polito 4*, Pietro Randazzo 5, Daniela Arosio 6,†, Pierfausto Seneci 2,* and Giovanni Piccoli 1,*

1 Department of Cellular, Computational and Integrative Biology (CIBIO), Via Sommarive 9, Povo, I-38123 Trento, Italy; giulia.frapporti@unitn.it (G.F.); giulia.assoni@unitn.it (G.A.)
2 Chemistry Department, Università Statale di Milano, Via Golgi 19, I-20133 Milan, Italy; eleonora.colombo@unimi.it (E.C.); hazem.ahmed@iit.it (H.A.)
3 Istituto Italiano di Tecnologia (IIT), Via Morego 30, I-16163 Genova, Italy
4 Istituto di Scienze e Tecnologie Chimiche (SCITEC) “Giulio Natta”, Consiglio Nazionale delle Ricerche (CNR), Via G. Fantoli 16/15, I-20138 Milan, Italy; laura.polito@scitec.cnr.it
5 Promidis srl, Via Olgettina 60, I-20132 Milan, Italy; p.randazzo@promidis.it
6 Istituto di Scienze e Tecnologie Chimiche (SCITEC) “Giulio Natta”, Consiglio Nazionale delle Ricerche (CNR), Via Golgi 19, I-20133 Milan, Italy; daniela.arosio@scitec.cnr.it
* Correspondence: pierfausto.seneci@unimi.it (P.S.); giovanni.piccoli@unimi.it (G.P.)
† These authors contributed equally to this work.

Abstract: The disaccharide trehalose is a well-established autophagy inducer, but its therapeutic application is severely hampered by its low potency and poor pharmacokinetic profile. Thus, we targeted the rational design and synthesis of trehalose-based small molecules and nano objects to overcome such issues. Among several rationally designed trehalose-centered putative autophagy inducers, we coupled trehalose via suitable spacers with known self-assembly inducer squalene to yield two nanolipid-trehalose conjugates. Squalene is known for its propensity, once linked to a bioactive compound, to assemble in aqueous media in controlled conditions, internalizing its payload and forming nanoassemblies with better pharmacokinetics. We assembled squalene conjugates to produce the corresponding nanoassemblies, characterized by a hydrodynamic diameter of 188 and 184 nm and a high stability in aqueous media as demonstrated by the measured Z-potential. Moreover, the nanoassemblies were characterized for their toxicity and capability to induce autophagy in vitro.

Keywords: autophagy inducers; trehalose; squalene conjugates; nanoassemblies; reduction-labile linkers; cancer; neurodegeneration

1. Introduction

Autophagy is a self-digestion process that allows the lysosomal degradation of misfolded protein aggregates and damaged organelles. Clearance of proteins plays a pivotal role in neuronal homeostasis; compromised protein clearance hampers central nervous system function and eventually leads to clinical manifestations [1,2]. Studies in complementary animal and cellular models suggest that autophagy may rescue from the pathological impact of misfolded protein aggregation in neurodegenerative disorders, including Alzheimer’s [3], and Parkinson’s disease [4]. Autophagy is instrumental to guarantee cellular integrity and viability, balancing the cell’s energy consumption and maintaining homeostasis [5,6]. In basal conditions, autophagic activity is low. Upon stress, autophagy upregulation will in turn boost cellular degradation, thus supporting the recycling of amino acids to assure the cellular integrity. Autophagy is known to interact with and control canonical apoptosis. As such, the role of autophagy in cancer has been extensively studied; autophagy deregulation is now considered a key feature for tumor progression [7]. Numerous tumor suppressor oncogenes have been identified as autophagic regulators, including the oncosuppressor p53, which may halt or induce autophagy depending on its cellular
localization and the underlying signaling pathways [8]. Accumulating evidence shows that downregulating key autophagic genes correlates with the promotion of tumorigenesis in some solid tumors such as breast, ovarian and prostate cancers [9].

Therefore, the pharmacological induction of autophagy may be an effective therapeutic strategy not only in several neurodegenerative disorders, including PD and AD [10], but also in cancer [11].

Trehalose is a naturally occurring disaccharide formed by an α,α-1,1-glucosidic bond between two α-glucose units. It is biosynthesized mostly by anhydrobiots, which include bacteria, yeast, nematodes, rotifers, tardigrades, certain crustaceans and insects [12]. Trehalose plays a pivotal role in various types of stress-tolerance, including radiation, cold and dehydration stress in these creatures [13–15]. Trehalose activates autophagy in vitro and in vivo [16]. Two main mechanisms have been proposed to explain the biological activity of trehalose. Namely, it blocks glucose transporters and thus triggers induced AMPK-dependent autophagy [17], or it acts by the lysosomal activation of the transcription factor TFEB, a master regulator of the autophagy-lysosome pathway function [18]. Recently, we found that trehalose can rescue protein aggregation and motor impairment in a rodent model of PD [4]. However, the pharmacokinetics properties of trehalose are poor. Previously, we characterized the pro-autophagic properties of gold nanoparticles functionalized with trehalose [19]. Here, we describe the synthesis and the biological activity of two squalene-trehalose constructs and of the corresponding nanoassemblies (NAs). More in detail, we characterized their toxicity and their efficacy in terms of autophagy induction in an in vitro model of cervical carcinoma.

2. Results

2.1. Synthesis of Mono- and Bis-Squalene-Trehalose Conjugates

In order to obtain either a mono- (target compound 1a—Sq-mono, 1:1 squalene-trehalose conjugate) or a bis-squalenylated trehalose construct (target compound 1b—Sq-bis, 2:1 squalene-trehalose conjugate), we envisaged the synthetic strategy described in Scheme 1.

![Scheme 1](image-url)

Scheme 1. Synthesis of mono- (1a) and bis- (1b) squalene-trehalose adducts for self-assembling organic nanovectors.

Namely, squalene-dithiolinker carboxylate 3 [20] was coupled in a 1:1 ratio with TMS-protected trehalose 2 [21] (step a, Scheme 1). Both TMS-protected mono-squalenylated 4a and bis-squalenylated trehalose 4b were isolated in poor, unoptimized yields after chromatography. Both intermediates 4a and 4b were deprotected with AcOH in refluxing
MeOH (step b, Figure 1), yielding pure 6-squalene-trehalose conjugate \(1a\) and 6,6′-bis-squalene-trehalose conjugate \(1b\) as self-assembling constructs.

**2.2. Assembly of Mono- and Bis-Squalene-Trehalose NAs**

The assembly of both NAs was carried out using a standardized method [20]. Namely, squalene-trehalose conjugates \(1a\) and \(1b\) were dissolved in THF (step a, Scheme 2) and then added dropwise to stirred MilliQ water, reaching a \(\approx2\) mg/mL concentration (step b). After stirring for 5 min, THF was thoroughly evaporated (step c, Scheme 2).

Both NAs \(5a\) and \(5b\) were obtained as opalescent solutions and were structurally characterized in terms of hydrodynamic diameter (HD) and Z-potential before submitting them to biology profiling as putative autophagy inducers. Their features are shown in Table 1.
Table 1. NAs 5a, b: structural characterization.

| Compound (NA) (mg/mL) | Polydispersity Index (PI) | Hydrodynamic Diameter (HD, nm) | Z-Potential (mV) |
|-----------------------|--------------------------|-------------------------------|------------------|
| 5a (0.6 mg/mL)        | 0.167 ± 0.018            | 188 ± 49                      | −37.13 ± 0.85    |
| 5b (0.6 mg/mL)        | 0.074 ± 0.013            | 184 ± 36                      | −43.55 ± 1.60    |

Dynamic light scattering (DLS) confirmed the formation of NAs in aqueous media. Their low polydispersity index values (PI < 0.2) confirmed the mono-dispersion of the colloidal solution of each NA, while their strongly negative Z-potential (<−35 mV) suggested a high electrostatic repulsion, i.e., good colloidal stability. Finally, hydrodynamic diameters were satisfyingly low for squalene-based NAs (<200 nm).

2.3. Biological Characterization of Trehalose-Based Small Molecules and NAs: Toxicity

First, we profiled the cytotoxicity and autophagy induction of our conjugates and NAs in a cellular model. In particular, we treated HeLa cultures for 24 h at 37 °C with either the two NAs 5a and 5b (at estimated adjusted concentrations of free trehalose in water equal to 10, 25 and 50 μM), their non-assembled squalene-trehalose precursors 1a and 1b (10, 25 and 50 μM) and each individual component of such constructs, namely 100 mM trehalose in water, 50 μM squalene, 50 μM 4,4′-dithiodibutyric acid (hereinafter linker) and relative vehicle (DMSO). At first, we determined the in vitro toxicity of each sample via the MTT assay. Upon 24 h treatment, 1b and its related NA 5b elicited a dose-dependent toxicity at concentrations higher than 10 μM (Figure 1A). In particular, both the non-assembled bis-squalene-trehalose precursor 1b and its related NA 5b showed significant cytotoxicity at 25 μM (≈65% viable cells with both 1b and NA 5b) and 50 μM (45% viable cells with 1b, ≈25% viable cells with NA 5b). Rather, mono-squalene-trehalose precursor 1a and its related NA 5a were not overtly toxic at 10 and 25 μM and triggered only minor toxicity at 50 μM (Figure 1B, ≈75% viable cells with both 1a and 5a).

2.4. Biological Characterization of Trehalose-Based Small Molecules and NAs: Efficacy

Next, we assessed whether the NAs, their non-assembled precursors and individual components induced autophagy upon 24 h of treatment. In particular, we tracked the mobility shift from LC3BI to LC3BII, which is a proxy for the induction of autophagy as well as the amount of LC3BII, itself related to the number of autophagosomes. α-Tubulin was used as an internal control in the assays. Squalene-trehalose precursor 1a did not activate
autophagy at tested concentrations (10 and 25 µM, Figures 2A and 3A). Conversely, 1b and both NAs efficiently enhanced autophagosome formation even at 10 µM, as suggested by the relative amount of LC3BII (Figures 2A–C and 3A). Considering the autophagic flux, NA 5b was already active at 10 µM, while NA 5a showed positive effects at ≥25 µM concentration (respectively, Figures 2B,C and 3B and Supplementary Figure S1).

The increase in LC3BII indicates the accumulation of autophagosomes and does not guarantee their autophagic degradation. However, if the amount of LC3BII further accumulates in presence of a lysosomal protease inhibitor, this would indicate the promotion of autophagic flux. Therefore, we analyzed the biological effect of trehalose (25 µM), NAs 5a (25 µM) and 5b (10 µM) in presence of bafilomycin (100 nM), a well-known lysosomal blocker [22]. In detail, we added bafilomycin during the last 2 h of the treatment with NAs. Noteworthy, we noticed that LC3BII further accumulated upon co-administration of 5b and bafilomycin (Figure 4A,B). In a complementary approach, we took advantage of a tandem fluorescent reporter GFP-mCherry-LC3B. Given the low pH of the autolysosome, the green fluorescence from the acid-sensitive GFP is lost upon fusion of the autophagosome with the lysosome. Conversely, the red fluorescence emitted by the acid-insensitive mCherry is not lost until the proteins are completely degraded. Such a double tag strategy allowed us to discriminate autophagosomes from autolysosomes [23,24].

Thus, we treated HeLa cells expressing the GFP-mCherry-LC3B reporter for 24 h with trehalose (positive control) and both NAs at the highest concentration lacking toxic effect, i.e., 10 µM for 5b and 25 µM 5a. We noticed that both 5b and 5a induced a significant increase of the number for both autophagosomes and autophagolysosomes (Figure 5A,B). The treatment did not alter the ratio between autophagosomes and autophagolysosomes, suggesting that it did not cause any gross alteration of the physiological autophagic flux (Figure 5C).

As our constructs and NAs included a disulfide bond connecting the squalene carrier and trehalose, we reasoned that a reducing agent may allow the release of functionalized trehalose through a prodrug-like mechanism. Thus, we investigated whether any intracellular reducing agent may play a role in the biological effect of the NAs.

Glutathione (GSH) is the major component of cellular antioxidant systems. Buthionine sulfoximine (BSO) depletes cellular GSH by inhibiting γ-glutamylcysteine synthetase (Figure 6A), a key enzyme in the GSH synthesis pathway [25]. We treated HeLa cells for 24 h with 5b (10 µM) and 5a (25 µM) either alone or in presence of 1 mM BSO. The treatment with BSO neither did affect significantly cell viability per se, nor modified the toxicity profile of our NAs (Figure 6B). Noteworthy, 1 mM BSO significantly impaired the effect of our NAs on the autophagic process by preventing the increase on autophagosome formation induced by 10 µM 5b or 25 µM 5a (Figures 6C and 7A,B).

Altogether, these observations suggest that NAs 5a and 5b induced autophagy upon intracellular release of trehalose.
Altogether, these observations suggest that NAs 5a and 5b induced autophagy upon intracellular release of trehalose.

**Figure 2.** Biological activity of trehalose, conjugates 1a and 1b and NAs 5a and 5b. We assessed LC3B conversion upon compound treatment by Western blotting. (A) Evaluation of autophagy induction in HeLa cells treated for 24 h with trehalose, 1b and 1a. Upon treatment, we analyzed tubulin, LC3BI and II levels by Western blotting. (B) Evaluation of autophagy induction in HeLa cells treated for 24 h with trehalose and 5b. Upon treatment, we analyzed α-tubulin, LC3BI and II levels by Western blotting. (C) Evaluation of autophagy induction in HeLa cells treated for 24 h with trehalose and 5a. Upon treatment, we analyzed α-tubulin, LC3BI and II levels by Western blotting.
Figure 3. Biological activity of trehalose, conjugates 1a and 1b and NAs 5a and 5b. Quantification of LC3BI, LC3BII and tubulin signals. (A) The graph shows LC3BII amount expressed as fold over α-tubulin. Data are expressed as mean ± S.E.; * < p < 0.05, ** p < 0.01 vs. control, n = 10–15. (B) The graph shows the LC3BII/LC3BI ratio. Each value was normalized on proper control. Data are expressed as mean ± S.E.; *** p < 0.001, ** p < 0.01, * p < 0.05 vs. control, n = 10–15.
Figure 4. Characterization of the effects of trehalose and NAs 5a and 5b on autophagy. We assessed LC3B conversion upon compound treatment by Western blotting. (A) Evaluation of autophagy induction in HeLa cells treated for 24 h with 25 µM trehalose, 25 µM 5a and 10 µM 5b. During the last 2 h of treatment, we added the known lysosomal blocker bafilomycin (100 nM, 2 h). Upon treatment, we analyzed tubulin and LC3BII levels by Western blotting. (B) The graph shows LC3BII amounts expressed as fold over α-tubulin. Data are expressed as mean ± S.E.; ** p < 0.01 vs. control, # p < 0.05 vs. control + bafilomycin, n = 8–10.
Figure 5. Assessment of autophagy by imaging approaches. We investigated the autophagic flux by a GFP-mCherry-LC3B reporter. Non-acidic autophagosomes appear as green and red dots, while autophagolysomes are red. (A) Image-based investigation of autophagy upon expression of the reporter GFP-mCherry-LC3B in HeLa cells treated for 24 h with trehalose (100 mM), 5b (10 µM) and 5a (25 µM). Scale bar = 10 µm. (B) The graph reports the number of autophagosomes (yellow) and autophagolysomes (red) present in each cell. Data are expressed as mean ± S.E.; * p < 0.05, ** p < 0.01 vs. control, n = 10–15 for each experiment, 3 independent experiments. (C) The graph reports the percentage of autophagosomes (yellow) and autophagolysomes (red) present in each cell. Data are expressed as mean ± S.E.; * p < 0.05, ** p < 0.01 vs. control, n = 10–15 for each experiment, 3 independent experiments.
Figure 6. The activity of NAs 5a and 5b is reduction-dependent in cells. We assessed the role of intracellular glutathione on NA activity by Western blotting. (A) In eukaryotic cells, de novo synthesis of reduced glutathione (GSH) occurs via a two-step ATP-requiring enzymatic process mediated by two different enzymes, \( \gamma \)-glutamylcysteine synthetase and glutathione synthase. Buthionine sulphoximine (BSO) is an inhibitor of gamma-glutamylcysteine synthetase and, consequently, lowers cellular GSH concentrations. (B) Cytotoxicity assay on HeLa cells treated for 24 h with BSO (1 mM) alone, or in combination with 5b (10 \( \mu \)M) or 5a (25 \( \mu \)M). Data are presented as mean \( \pm \) SE; \( n = 10–15 \). (C) Evaluation of autophagy induction in HeLa cells treated for 24 h with trehalose (100 mM), BSO (1 mM), 5a (25 \( \mu \)M), 5b (10 \( \mu \)M), BSO (1 mM) + 5a (25 \( \mu \)M) and BSO (1 mM) + 5b (10 \( \mu \)M). Upon treatment, we analyzed \( \alpha \)-tubulin, LC3BI and II levels by Western blotting.
3. Discussion

Trehalose is a powerful autophagic inducer that holds promising therapeutic opportunities. A major obstacle against its application as a therapeutic agent is its poor permeability across biological membranes. In fact, trehalose is highly hydrophilic, thus hampering its passive cell permeation [15]. Mammalian cells do not express trehalose transporters in their membranes. Moreover, the trehalose catabolic enzyme, trehalase, is highly expressed in the gut, causing trehalose hydrolysis to glucose upon *per os* administration [26]. Thus, trehalose-based treatment in humans is cumbersome and requires high dosages. For example, a clinical trial to test the efficacy of trehalose in treating oculopharyngeal muscular dystrophy entailed trehalose administration via a 1 h IV infusion at a 0.75 g/kg dosage ([ClinicalTrials.gov Identifier: NCT04226924](https://clinicaltrials.gov/ct2/show/NCT04226924), accession date: 14 April 2022).

![Figure 7](image-url)
Nano lipid-drug conjugates couple a drug to biocompatible lipids and may represent a powerful tool to ameliorate the pharmacokinetics and improve the therapeutic index of the original drugs [27]. In particular, nano-assembled squalene-based conjugates have been successfully exploited in several therapeutic applications [28]. In water, squalene-based conjugates spontaneously assemble into NAs which enclose the bioactive molecule. NAs are typically internalized by the cells through clathrin-dependent and -independent endocytic pathways [29].

Squalene-based NAs are an attractive strategy to achieve intracellular delivery of trehalose, thus overcoming its poor permeability profile and possibly reducing its dosage in preclinical and clinical testing. However, our previous attempt to improve trehalose pharmacological activity via a squalene-based NA mostly failed [21]. Previously, we employed NAs based on covalent bound squalene-trehalose conjugates. As such, upon internalization, those NAs disassembled and released the unmodified construct, i.e., trehalose covalently bound to squalene. We reasoned that such a bulky squalene structure may significantly hamper the biological activity of trehalose.

Here, instead, we chose to conjugate squalene and trehalose via a biologically labile linker. In particular, we coupled two chemical entities via a biolabile disulfide bond. In eukaryotic cells, disulfide bond stability tightly depends on the pH. In physiological conditions, disulfide bond formation happens principally in the oxidizing environment of the endoplasmic reticulum. Conversely, sulfhydryl groups of cysteine residues (Cys-SH) remain reduced at physiological pH in the reducing environment of the cytoplasm. Thus, the cytoplasm disfavors the existence of disulfide bonds. Accordingly, we designed the disulfide bond-containing NAs here described to facilitate the release of trehalose. Upon cellular internalization of NAs and subsequent disulfide bond reduction, trehalose is released with one (5a) or two (5b) short alkylthiol chains, which should eventually be aspecifically cleaved in the cytoplasm by esterases, releasing free trehalose.

Trehalose-containing NAs demonstrated a higher efficacy than free trehalose in terms of autophagy induction. Such an effect was dependent on the intracellular reduction of the disulfide bond, after NA internalization. Upon reduction of cellular GSH, we noticed a significant decline of the biological activity of our NAs. Notwithstanding their different composition and molecular weight, 5a and 5b showed a similar hydrodynamic diameter. Interestingly, 5b demonstrated a higher effect on autophagy. The lack of an overt effect of 5a once co-administered with bafilomycin may be due to the specific experimental conditions, as we may need to optimize timing and compound concentration. Conversely, we believe that the two residues of squalene present in compound 5b self-assemble in order to display on the outer surface the trehalose residue. Therefore, the resulting bis-squalenylated nanoassemblies 5b have a more hydrophobic core, do not increase their hydrodynamic diameter in respect to monosqualenylated 5a, and may have higher permeability through the cellular membrane.

Finally, we noticed that our NAs induced autophagy at a low concentration and showed cytotoxicity at a higher concentration in HeLa cells, a well-established cellular model of cervical carcinoma. Indeed, our NAs need GSH to release trehalose, and this may stress such cells; however, pharmacological reduction of GSH did not overtly hamper cell viability. The transient release of trehalose with one (5a) or two (5b) short-lived alkylthiol chains may contribute to the observed cytotoxicity of such NAs. Conversely, autophagy is involved in several mechanisms, controlling cellular viability and integrity. Therefore, in our in vitro model, autophagic induction may precede cancer cell death. Indeed, autophagy may act as a tumor suppressor in the initial stages by clearing any potentially harmful organelle and protein and, eventually, may induce cancer cell death [11,30]. However, in the advanced stages of cancer, autophagy may help cancer cells to handle stressful conditions and assist them in their survival, as reviewed in [31]. Clearly, a full understanding of the potential of autophagy as a therapeutic target in cancer requires further studies.
4. Conclusions

Current data support the hypothesis that autophagy modulation could arise as a new therapeutic avenue for the treatment of multiple disorders, including cancer and neurodegenerative diseases. While bona fide autophagy modulators are not yet included in clinical practice, ongoing investigations will lead to the development of safe autophagy modulators to be administered to patients.

In particular, squalene-based NA 5b has been shown to improve trehalose pharmacological properties, but further investigation is needed to refine our knowledge of its properties and improve our NA lead for in vivo testing.

5. Materials and Methods
5.1. Synthesis
5.1.1. General

Oven-dried glassware was used to carry out chemical reactions, and dry solvents under nitrogen atmosphere were employed. Solvents were purchased from Sigma Aldrich and used as such. Chemical reagents were also purchased from Sigma Aldrich and checked for integrity before using them. Direct phase flash chromatography columns were run with silica gel (240–400 mesh, Merck, Darmstadt, Germany). Reaction monitoring by thin layer chromatography (TLC) entailed Merck-precoated 60F_{254} plates. Reactions were monitored by TLC on silica gel, using as a direct detection method UV light at 254 nm, or by charring either with a 50% H_{2}SO_{4} or with a 1% permanganate solution. \( ^{1}\)H-NMR and \( ^{13}\)C-NMR spectra were recorded in either CDCl_{3}, CD_{3}OD or DMSO-d_{6}, depending on compounds’ solubility, on Bruker DRX-400 and Bruker DRX-300 instruments. Chemical shifts (\( \delta \)) for proton and carbon signals are quoted relatively to tetramethylsilane (TMS) as an internal standard and expressed in parts per million (ppm). Electrospray ionization (ESI) mass spectrometry (MS) spectra were recorded using a Waters Micromass Q-Tof micro mass instrument, while high resolution (HR)-ESI mass spectra were recorded on an FT-ICR APEX-II spectrometer (Bruker Daltonics, Billerica, MA, USA).

5.1.2. Synthesis of Mono Dithio-Dibutyroate Squalenoyl-hexaTMS-Trehalose 4a and Bis Dithio-Dibutyroate Squalenoyl-hexaTMS-Trehalose 4b

To a stirred solution of hexaTMS-protected trehalose 2 (317 mg, 0.409 mmol) in dry toluene (12.7 mL) at rt under nitrogen atmosphere, EDC·HCl (78.5 mg, 0.409 mmol) was added, followed by DMAP (5.0 mg, 0.0409 mmol). The carboxysqualene-linker adduct 3 (298 mg, 0.491 mmol) was added after 30 min, the reaction mixture was heated at 50 °C and further stirred for 46 h. Reaction completion was confirmed via TLC (eluent mixture: 9:1 n-hexane/AcOEt). Then, the solvent was removed at reduced pressure, and the resulting crude oil was purified by direct silica gel flash chromatography (eluent mixture: 9:1 n-hexane/AcOEt) to provide pure 4a (168 mg, 0.123 mmol, 30% yield) and pure 4b (112 mg, 0.0573 mmol, 14% yield) as two colorless oils.

**Analytical characterization 4a:**

\( ^{1}\)H-NMR (CDCl_{3}, 400 MHz): \( \delta \) (ppm) = 5.19–5.05 (m, 5H), 4.93–4.89 (m, 2H), 4.31 (dd, \( J = 11.8, 2.1 \) Hz, 1H), 4.15–3.95 (m, 4H), 3.93–3.78 (m, 3H), 3.71–3.66 (m, 2H), 3.53–3.38 (m, 4H), 2.73–2.70 (m, 4H), 2.52–2.41 (m, 4H) 2.11–1.96 (m, 18H), 1.75–1.69 (m, 2H), 1.68 (s, 3H), 1.62–1.57 (m, 15H), 1.29–1.22 (m, 4H), 0.34–0.07 (m, 54H).

\( ^{13}\)C-NMR (CDCl_{3}, 101 MHz): \( \delta \) (ppm) 173.0, 172.9, 135.1, 135.0, 134.9, 133.6, 131.3, 125.1, 124.41, 124.38, 124.29, 124.27, 94.5, 94.4, 73.4, 73.3, 73.0, 72.8, 72.6, 71.9, 71.4, 70.7, 64.3, 63.5, 61.7, 39.76, 39.73, 39.68, 37.8, 37.6, 35.8, 32.6, 32.4, 29.7, 28.3, 26.9, 26.8, 26.68, 26.67, 25.7, 24.2, 24.0, 17.7, 16.06, 16.05, 16.01, 15.9, (1.0, 0.90, 0.86, 0.2, 0.1 = 18C).

**MS (ESI*)**, \( m/z \): calcld for C_{65}H_{126}O_{14}S_{2}Si_{6} 1362.72, found 1385.71 (M + Na*).

**4b:**

\( ^{1}\)H-NMR (CDCl_{3}, 400 MHz): \( \delta \) (ppm) = 5.21–5.08 (m, 10H), 4.96–4.91 (m, 2H), 4.34–4.27 (m, 2H), 4.13–3.97 (m, 8H), 3.92 (t, \( J = 8.9 \) Hz, 2H), 3.53–3.45 (m, 4H), 2.78–2.70 (m, 8H),
13C-NMR (CDCl₃, 101 MHz): δ(ppm) = 173.8 (2C), 173.6 (2C), 135.0 (2C), 134.9 (2C), 134.8 (2C), 133.6 (2C), 131.2 (2C), 125.1 (2C), 124.4 (4C), 124.3 (4C), 94.4 (2C), 73.5 (2C), 72.7 (2C), 71.9 (2C), 70.7 (2C), 63.9 (2C), 63.3 (2C), 39.7 (4C), 35.8 (2C), 34.3 (2C), 34.1 (2C), 29.7 (2C), 29.1 (6C), 28.8 (2C), 28.2 (4C), 26.9 (2C), 26.8 (2C), 26.6 (4C), 25.7 (4C), 25.0 (2C), 24.7 (2C), 17.7 (2C), 16.0 (4C), 15.8 (2C), (1.0, 0.9, 0.4, 0.2 = 18C).

**MS (ESI⁺), m/z:** calcd for C₁₀₀H₈₂O₁₇S₄Si₆ 1951.09, found 1974.13 (M + Na⁺).

5.1.3. Synthesis of Mono Dithio-Dibutyroate Squalenoyl-Trehalose 1a

To a stirred solution of 4a (120 mg, 0.0880 mmol) in MeOH (1.3 mL) at rt, acetic acid (5.3 µL, 0.0880 mmol) was added by syringe; the resulting reaction mixture was warmed to 40 °C and left under stirring overnight. Reaction completion was confirmed via TLC (elucent mixture: 9:1 n-hexane/AcOEt) so that the solvent was removed at reduced pressure. The resulting crude solid was purified by direct silica gel flash chromatography (elucent mixture: 85:15 CH₂Cl₂/MeOH) to yield pure 1a (80.2 mg, 0.0854 mmol, 90% yield) as a white solid.

**Analytical characterization**

**1H NMR** (DMSO-d₆, 400 MHz): δ(ppm) = 5.17–5.03 (m, 6H), 4.88 (dd, J = 3.9, 2.4 Hz, 2H), 4.85 (t, J = 3.9 Hz, 1H), 4.77 (dd, J = 5.0, 2.7 Hz, 2H), 4.68 (dd, J = 6.1, 2.2 Hz, 2H), 4.34 (t, J = 5.9 Hz, 1H), 4.29–4.21 (m, 1H), 4.10–4.02 (m, 1H), 3.97 (t, J = 6.6 Hz, 2H), 3.95–3.88 (m, 1H), 3.69–3.61 (m, 1H), 3.57–3.54 (m, 3H), 3.51–3.43 (m, 1H), 3.30–3.21 (m, 2H), 3.19–3.08 (m, 8H), 2.76–2.66 (m, 5H), 2.41 (q, J = 6.9 Hz, 4H), 2.07–1.83 (m, 2H), 1.70–1.60 (m, 5H), 1.56 (s, 15H).

**13C-NMR** (DMSO-d₆, 101 MHz): δ(ppm): 172.4, 172.2, 134.3, 134.38, 134.31, 133.6 (2C), 124.4, 124.14, 124.08 (2C), 123.9, 98.22, 98.15, 72.84, 72.77, 72.61, 71.57, 71.47, 70.1 (2C), 69.6, 63.5, 63.3, 60.8, 39.4, 39.2, 36.7, 36.7, 35.3, 32.0 (2C), 27.8 (2C), 26.3, 26.2, 26.0 (2C), 25.5, 24.0, 23.9, 17.6, 15.8 (4C), 15.7.

**MS (ESI⁺), m/z:** calcd for C₄₂H₇₀O₁₄S₂ 930.48, found 953.51 (M + Na⁺).

5.1.4. Synthesis of Bis Dithio-Dibutyroate Squalenoyl-Trehalose 1b

To a stirred solution of 4b (65.2 mg, 0.0334 mmol) in MeOH (1 mL) at rt, acetic acid (1.9 µL, 0.0334 mmol) was added by syringe, the reaction mixture was warmed and stirred at 40 °C overnight. After checking reaction completion by TLC (elucent mixture: 9:1 n-hexane/AcOEt), the solvent was removed at reduced pressure, and a crude residue was purified by direct silica gel flash chromatography (elucent mixture: 85:15 CH₂Cl₂/MeOH) to provide pure target 1b (51.2 mg, 0.0310 mmol, 94% yield) as a white solid.

**Analytical characterization**

**1H-NMR** (DMSO-d₆, 400 MHz): δ(ppm) = 5.15–5.00 (m, 12H), 4.95–4.85 (m, 2H), 4.83 (d, J = 3.5 Hz, 2H), 4.80–4.73 (m, 2H), 4.26 (d, J = 10.4 Hz, 2H), 4.09–4.02 (m, 2H), 3.96 (t, J = 6.6 Hz, 4H), 3.94–3.86 (m, 2H), 3.62–3.49 (m, 4H), 3.32–3.23 (m, 4H), 3.17–3.08 (m, 2H), 2.71 (td, J = 7.4, 2.7 Hz, 8H), 2.40 (q, J = 7.0 Hz, 8H), 1.95 (ddq, J = 37.7, 21.4, 6.9 Hz, 44H), 1.68–1.61 (m, 10H), 1.55 (s, 30H).

**13C-NMR** (DMSO-d₆, 101 MHz): δ(ppm): 172.7 (2C), 172.6 (2C), 134.85 (2C), 134.80 (2C), 134.74 (2C), 134.0 (2C), 131.1 (2C), 124.9 (2C), 124.6 (2C), 124.51 (2C), 124.47 (2C), 124.36 (2C), 94.1 (2C), 73.2 (2C), 71.9 (2C), 70.5 (2C), 70.2 (2C), 63.9 (2C), 63.7 (2C), 39.7 (2C), 39.6 (2C), 37.2 (2C), 37.1 (2C), 35.7 (2C), 32.5 (4C), 29.1 (4C), 28.2 (4C), 26.9 (2C), 26.8 (2C), 26.7 (2C), 26.4 (2C), 25.9 (2C), 24.9 (2C), 24.4 (2C), 18.0 (2C), 16.4 (2C), 16.2 (2C), 16.1 (2C).

**MS (ESI⁺), m/z:** calcd for C₆₂H₁₃₄O₁₇S₄Si₆ 1518.85, found 1541.84 (M + Na⁺).

**NA assembly and characterization**

**Mono—Sq-NA 5a.** The squalene-trehalose conjugate 1a (4.0 mg) was dissolved in THF (1 mL), the clear solution was slowly added to magnetically stirred (500 rpm) MilliQ grade distilled water (2 mL) in a round bottom flask, and the resulting solution was stirred for 5 additional min. The solvent was then thoroughly evaporated at reduced
pressure, obtaining pure mono—Sq-NA 5a as an opalescent suspension (2 mL, 2 mg/mL), in accordance with standard solvent evaporation protocols [32].

Bis—Sq-NA 5b. The same procedure for Mono—Sq-NA 5a was followed, obtaining pure bis—Sq-NA 5b as opalescent suspension (2 mL, 2 mg/mL).

**NA Characterization.** A 90 Plus Particle Size Analyzer (Brookhaven Instrument Corporation, Holtsville, NY, USA) was used to determine the hydrodynamic diameter of our NAs by dynamic light scattering (DLS), operating a solid-state laser ($\lambda = 661$ nm) at 15 mW, and with a scattering angle of 90 °C. The same instrument equipped with an AQ-809 electrode, operating at an applied voltage of 120 V at 25 °C, was used to determine the $\zeta$-potential of our NAs.

In detail, each NA sample was prepared first by diluting it at 0.6 mg/mL and by sonicating for 3 min. Then, each sample was analyzed in ten independent measurements lasting 60 s each. The hydrodynamic diameters of our NAs were calculated using the Mie theory, assuming refractive index values and absolute viscosity of the medium to be, respectively, 0.890 cP and 1.33. Their Z-potentials were extrapolated using the Smoluchowski theory, from the electrophoretic mobility of our NAs.

5.2. **Cell Cultures**

We cultured HeLa cells (ATCC: CCL-2) in DMEM (Euroclone, Pero, Italy) medium, supplemented with 10% fetal bovine serum (FBS; Euroclone), 1% penicillin/streptomycin (Gibco, 15140122) and 1% L-glutamine (Gibco, Grand Island, NV, USA) in a humidified atmosphere of 5% CO$_2$ at 37 °C. Cells were passaged one or two times a week depending on confluency using Trypsin-EDTA 0.05% (Gibco, 25300054).

5.3. **Cytotoxicity Assay**

To measure culture viability, we performed the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. HeLa cells were cultured in a 96-well plate at a concentration of 5 $\times$ 10$^3$ cell/cm$^2$ and incubated at 37 °C for 24 h. Then, the cell medium was replaced with MTT diluted in PBS at a final concentration of 0.25 mg/mL for 30 min at 37 °C. Afterwards, the MTT solution was carefully removed, and formazan precipitates collected in 200 $\mu$L of DMSO. The absorbance measured at 570 nm using a spectrophotometer reflects cell vitality. Relative cell vitality was expressed as fold over control, set at 100%.

5.4. **Autophagy Assay**

We monitored autophagy by Western blotting as previously reported [19]. First, cells were washed in PBS and lysed in RIPA buffer (150 mM NaCl, 50 mM HEPES, 0.5% NP40, 1% sodium-deoxycholate) containing protease inhibitors (Merck). After collecting the material, samples were briefly vortexed three times every 10 min and then any solid was removed by centrifugation at 10,000× g for 10 min. We performed all experimental procedures at 4 °C. The determination of lysates’ protein concentrations was carried out via Bradford assay (Bio-Rad Laboratories, Segrate, Italy). For Western blotting experiments, an equal amount of proteins was diluted with 0.25% Laemmli buffer and boiled at 95 °C for 10 min. We ran protein samples onto 15% SDS-PAGE gels. After gel electrophoresis, the proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane (Sigma-Aldrich, St. Louis, MO, USA) at 90 V for 90 min at 4 °C. Used primary antibodies (source in parentheses) include mouse anti-LC3B, 1:500 (Enzo LifeScience, New York, NY, USA) and mouse anti $\alpha$-tubulin 1:5000 (Sigma Aldrich), which were applied overnight in blocking buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20, and 5% nonfat dry milk). We detected proteins by the ECL prime detection system (GE Healthcare, Chicago, IL, USA). We acquired an ECL signal via the imaging ChemiDoc Touch Imaging system Version 2.1.0.35 (Bio-Rad Laboratories). We measured the optical density of the specific bands with ImageLab software Version 6.0.1 build 34 (2017, Bio-Rad Laboratories, Inc.).
5.5. Autophagosome–Lysosome Fusion Assay

The autophagosome–lysosome fusion assay was performed in HeLa cells transfected with the mCherry- and GFP-tagged LC3B [23], using PEI (jetPEI® reagent). One day after transfection, we treated cells with trehalose (100 mM), 5a (25 µM) and 5b (10 µM) for 24 h. At the end of the treatment, we fixed cells with 4% paraformaldehyde (10 min, rt). We mounted the cover slips with prolonged reagent (Life Technologies, Carlsbad, CA, USA). Images were acquired with the optical microscope ZEISS AXIO IMAGER M2 using a plan-Apochromat 40× objective and 0.102 µm × 0.102 µm pixel size. We counted the numbers of mCherry and/or GFP-positive puncta in each cell using ImageJ.

5.6. Statistical Analysis

All data are mean ± standard error of the mean (SE). We exploited GraphPad Prism to analyze our entire data set. We applied unpaired Student’s t-test (two classes) or ANOVA followed by Tukey’s post hoc test (more than two classes). The number of experiments (n) and level of significance (p) were indicated throughout the text.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics14040862/s1, Figure S1: autophagy induction in HEK293 cells and raw images of the western-blots included in the manuscript.

Author Contributions: G.F., E.C., H.A., G.A., P.R., L.P. and D.A. performed experiments. P.S. and G.P. analyzed the data and wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding: G.P. received support by Fondazione Telethon (grant TDPG00514TA), MIUR (PRIN-2017ENN4FY), and Fondazione Cariplo (project 2019-3415).

Data Availability Statement: Data are available contacting the corresponding authors upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interests.

References
1. Deleidi, M.; Maetzler, W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in lewy body disorders. Int. J. Alzheimers. Dis. 2012, 2012, 391438. [CrossRef] [PubMed]
2. Kumar, D.; Ambasta, R.K.; Kumar, P. Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies. Ageing Res. Rev. 2020, 61, 101078. [CrossRef] [PubMed]
3. Zhang, W.; Wang, J.; Yang, C. Celastrol, a TFEB (transcription factor EB) agonist, is a promising drug candidate for Alzheimer disease. Autophagy 2022, 6, 1–3. [CrossRef] [PubMed]
4. Pischedda, F.; Cirmaru, M.D.; Ponzoni, L.; Sandre, M.; Biosa, A.; Carrion, M.P.; Marin, O.; Morari, M.; Pan, L.; Greggio, E.; et al. LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation. Brain 2021, 144, 1509–1525. [CrossRef] [PubMed]
5. Rahman, M.A.; Rhim, H. Therapeutic Implication of Autophagy in Neurodegenerative Diseases. BMB Rep. 2017, 50, 345–354. [CrossRef] [PubMed]
6. Rahman, M.A.; Cho, Y.; Nam, G.; Rhim, H. Antioxidant Compound, Oxyresveratrol, Inhibits APP Production through the AMPK/ULK1/mTOR mediated Autophagy Pathway in Mouse Cortical Astrocytes. Antioxidants 2021, 10, 108. [CrossRef] [PubMed]
7. White, E. The Role for Autophagy in Cancer. J. Clin. Investig. 2015, 125, 42–46. [CrossRef] [PubMed]
8. Mrakovcic, M.; Fröhlich, L.F. p53-Mediated Molecular Control of Autophagy in Tumor Cells. Biomolecules 2018, 8, 14. [CrossRef]
9. Khan, A.; Singh, V.K.; Thakral, D.; Gupta, R. Autophagy in acute myeloid leukemia: A paradoxical role in chemoresistance. Clin. Transl. Oncol. 2022, ahead of print. [CrossRef]
10. Klionsky, D.J. Autophagy in major human diseases. EMBO J. 2021, 40, e108863. [CrossRef]
11. Mucalhy Levy, J.M.; Thorburn, A. Autophagy in cancer: Moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ. 2020, 27, 843–857. [CrossRef]
12. Khan, A.A.; Stocker, B.L.; Timmer, M.S.M. Trehalose glycolipids–synthesis and biological activities. Carbohydr. Res. 2012, 356, 25–36. [CrossRef] [PubMed]
13. Crowe, J.H.; Crowe, L.M.; Chapman, D. Preservation of membranes in anhydrobiotic organisms: The role of trehalose. Science 1984, 223, 701–703. [CrossRef] [PubMed]
14. Argüelles, J.-C. Why can’t vertebrates synthesize trehalose? J. Mol. Evol. 2014, 79, 111–116. [CrossRef] [PubMed]
15. Abazari, A.; Meimetis, L.G.; Budin, G.; Bale, S.S.; Weissleder, R.; Toner, M. Engineered Trehalose Permeable to Mammalian Cells. *PLoS ONE* **2015**, *10*, e0130323. [CrossRef] [PubMed]

16. Stacchiotti, A.; Corsetti, G. Natural Compounds and Autophagy: Allies against Neurodegeneration. *Front. Cell Dev. Biol.* **2020**, *8*, e82232. [CrossRef]

17. DeBosch, B.J.; Heitmeier, M.R.; Mayer, A.L.; Higgins, C.B.; Crowley, J.R.; Kraft, T.E.; Chi, M.; Newberry, E.P.; Chen, Z.; Finck, B.N.; et al. Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis. *Sci. Signal* **2016**, *9*, ra21. [CrossRef]

18. Rusmini, P.; Cortese, K.; Crippa, V.; Cristofani, R.; Cicardi, M.E.; Ferrari, V.; Vezzoli, G.; Tedesco, B.; Meroni, M.; Messi, E.; et al. Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration. *Autophagy* **2019**, *15*, 631–651. [CrossRef]

19. Assoni, G.; Frapporti, G.; Colombo, E.; Gornati, D.; Perez-Carrion, M.D.; Polito, L.; Seneci, P.; Piccoli, G.; Arosio, D. Trehalose-based neuroprotective autophagy inducers. *Bioorg. Med. Chem. Lett.* **2021**, *40*, 127929. [CrossRef]

20. Borrelli, S.; Christodoulou, M.S.; Ficarra, I.; Silvani, A.; Cappelletti, G.; Cartelli, D.; Damia, G.; Ricci, F.; Zucchetti, M.; Dosio, F.; et al. New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A. *Eur. J. Med. Chem.* **2014**, *85*, 179–190. [CrossRef]

21. Colombo, E.; Biocotino, M.; Frapporti, G.; Randazzo, P.; Christodoulou, M.S.; Piccoli, G.; Polito, L.; Seneci, P.; Passarella, D. Nanolipid-trehalose conjugates and nano-assemblies as putative autophagy inducers. *Pharmaceutics* **2019**, *11*, E422. [CrossRef]

22. Yoshimori, T.; Yamamoto, A.; Moriyama, Y.; Futai, M.; Tashiro, Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H+-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. *J. Biol. Chem.* **1991**, *266*, 17707–17712. [CrossRef]

23. Kimura, S.; Noda, T.; Yoshimori, T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. *Autophagy* **2007**, *3*, 452–460. [CrossRef]

24. Pankiv, S.; Clausen, T.H.; Lamark, T.; Brech, A.; Bruun, J.-A.; Outzen, H.; Øvervatn, A.; Bjørkøy, G.; Johansen, T. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J. Biol. Chem.* **2007**, *282*, 24131–24145. [CrossRef]

25. Griffith, O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. *Free Radic. Biol. Med.* **1999**, *27*, 922–935. [CrossRef]

26. Kalf, G.F.; Rieder, S.V. The purification and properties of trehalase. *J. Biol. Chem.* **1958**, *230*, 691–698. [CrossRef]

27. Adhikari, P.; Pal, P.; Das, A.K.; Ray, S.; Bhattacharjee, A.; Mazumder, B. Nano lipid-drug conjugate: An integrated review. *Int. J. Pharm.* **2017**, *529*, 629–641. [CrossRef]

28. Couvreur, P.; Stella, B.; Reddy, L.H.; Hillaireau, H.; Dubernet, C.; Desmaële, D.; Lepêtre-Mouelhi, S.; Rocco, F.; Dereuddre-Bosquet, N.; Clayton, P.; et al. Squalenoyl nanomedicines as potential therapeutics. *Nano Lett.* **2006**, *6*, 2544–2548. [CrossRef]

29. Sémiramoth, N.; Di Meo, C.; Zouhiri, F.; Said-Hassane, F.; Valetti, S.; Gorges, R.; Nicolas, V.; Poupaert, J.H.; Chollet-Martin, S.; Desmaële, D.; et al. Self-assembled squalenoylated penicillin bioconjugates: An original approach for the treatment of intracellular infections. *ACS Nano* **2012**, *6*, 3820–3831. [CrossRef]

30. Sui, X.; Chen, R.; Wang, Z.; Huang, Z.; Kong, N.; Zhang, M.; Han, W.; Lou, F.; Yang, J.; Zhang, Q.; et al. Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. *Cell Death Dis.* **2013**, *4*, e838. [CrossRef]

31. Chavez-Dominguez, R.; Perez-Medina, M.; Lopez-Gonzalez, J.S.; Galicia-Velasco, M.; Aguilar-Cazares, D. The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to Pro-tumor Activity. *Front. Oncol.* **2020**, *10*, 578418. [CrossRef]

32. Battaglia, L.; Gallarate, M. Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery. *Expert Opin. Drug Deliv.* **2012**, *9*, 497–508. [CrossRef]